Editas Medicine, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions. Its current development efforts include in vivo and ex vivo programs aimed at areas such as hematology, cardiovascular disease, and other severe disorders with limited treatment options. Editas Medicine also maintains collaborations and intellectual property positions that support its research platform and pipeline. Headquartered in Cambridge, Massachusetts, the company plays a specialized role in the gene editing market by advancing experimental medicines intended to address diseases at the DNA level.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Gilmore O'Neill M.D.
- Employees
- 246
- Headquarters
- Cambridge, MA, United States
- Website
- www.editasmedicine.com